MARKET

PRPO

PRPO

PRECIPIO
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.580
-0.140
-5.15%
After Hours: 2.510 -0.07 -2.71% 19:54 02/25 EST
OPEN
2.710
PREV CLOSE
2.720
HIGH
2.750
LOW
2.550
VOLUME
230.19K
TURNOVER
--
52 WEEK HIGH
8.00
52 WEEK LOW
0.5500
MARKET CAP
44.45M
P/E (TTM)
-1.5239
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
4 Penny Stocks You Might've Missed If You're Ignoring Biotech Right Now
Feb 24, 2021 (Penny Stocks via COMTEX) -- Are Biotech Penny Stocks Part Of Your Strategy In 2021? It's February 2021, and the markets are at all-time highs....
Penny Stocks · 1d ago
Precipio launches COVID-19 antibody testing at point-of-care
Precipio ([[PRPO]] -6.6%) has begun to roll out Nirmidas Biotech's COVID-19 antibody tests following receipt of an Emergency Use Authorization from the FDA.The test, produced by Nirmidas, a biotech company based in Palo Alto, CA is the first US-based produ...
Seekingalpha · 01/28 20:22
BRIEF-Precipio Launches Covid-19 Antibody Testing At Point-Of-Care
reuters.com · 01/28 14:32
Precipio Launches COVID-19 Antibody Testing at Point-of-Care
Following the receipt of FDA EUA by Nirmidas, Precipio begins market roll out to POCNEW HAVEN, Conn., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that following receipt of an Emergency Use ...
GlobeNewswire · 01/28 14:30
Precipio Launches COVID-19 Antibody Testing at Point-of-Care
Following the receipt of FDA EUA by Nirmidas, Precipio begins market roll out to POCNEW HAVEN, Conn., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that following receipt of an Emergency Use ...
GlobeNewswire · 01/28 14:30
Precipio Launches COVID-19 Antibody Testing at Point-of-Care
Following the receipt of FDA EUA by Nirmidas, Precipio begins market roll out to POCNEW HAVEN, Conn., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that following receipt of an Emergency Use ...
GlobeNewswire · 01/28 14:30
NOK, SRGA among premarket losers
Helius Medical Technologies (HSDT) -17%.Avinger (AVGR) -12%.Cango (CANG) -11%.OncoCyte (OCX) -10%.Obalon Therapeutics (OBLN) -10%.Dolphin Entertainment (DLPN) -9%.Surgalign Holdings (SRGA) -8% after pricing equity offering at $1.50.Vertex Energy (VTNR) -7%...
Seekingalpha · 01/28 13:17
Precipio signs Hemescreen deals with two leading oncology groups in the U.S.
Precipio (PRPO) has signed agreements with two of the largest oncology practices in the US for the use of its Reagent Rental Program HemeScreen.During the coming weeks, both practices,  West Cancer Center of Memphis and New York
Seekingalpha · 01/20 15:13
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRPO. Analyze the recent business situations of PRECIPIO through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PRPO stock price target is 4.150 with a high estimate of 6.30 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 31
Institutional Holdings: 865.42K
% Owned: 5.02%
Shares Outstanding: 17.23M
TypeInstitutionsShares
Increased
6
167.00K
New
12
65.85K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-1.97%
Healthcare Equipment & Supplies
-1.74%
Key Executives
Chairman/Director
Douglas Fisher
President/Chief Executive Officer/Director
Ilan Danieli
Chief Financial Officer
Carl Iberger
Vice President/Director of Sales
Douglas Sites
Chief Operating Officer
Ahmed Sabet
Other
Ori Karev
Other
Stephen Miller
Director
David Cohen
Director
Mark Rimer
Independent Director
Jeffrey Cossman
Independent Director
Kathleen LaPorte
Independent Director
Richard Sandberg
  • Dividends
  • Splits
  • Insider Activity
No Data
About PRPO
Precipio, Inc. is a cancer diagnostics company providing diagnostic products and services to the oncology market. The Company’s platform is designed to provide physicians and their patients access to necessary technology in order to provide diagnoses. The Company is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a proprietary culture media that addresses the problem of selective culturing-by creating a universal media that enables simultaneous culturing of hematopoietic cell lineages. ICP is a specimen enrichment technology that increases the sensitivity of molecular based tests. The Company has developed a screening panel for genes in one rapid scanning panel, HemeScreen.

Webull offers kinds of Precipio Inc stock information, including NASDAQ:PRPO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRPO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRPO stock methods without spending real money on the virtual paper trading platform.